US-based biotech company eFFECTOR Therapeutics has secured $38.6m in a series C venture financing round led by Pfizer Venture Investments (PVI).
The company plans to use the funds to progress the development of its MNK1/2 inhibitor, eFT508, into Phase II development.
VenatoRx Pharmaceuticals has secured $42m in a series B venture financing round led by Versant Venture Management.
The US-based biopharmaceutical company plans to use the funds for the development of its product portfolio.
Kezar Life Sciences, a biopharmaceutical company based in the US, has secured $50m in a series B venture financing round led by Cormorant Asset Management.
The company will direct the funds towards the development of its immunoproteasome inhibitor KZR-616.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData